330 related articles for article (PubMed ID: 18692688)
1. Epigenetics in acute myeloid leukemia.
Plass C; Oakes C; Blum W; Marcucci G
Semin Oncol; 2008 Aug; 35(4):378-87. PubMed ID: 18692688
[TBL] [Abstract][Full Text] [Related]
2. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
Kogan AA; Lapidus RG; Baer MR; Rassool FV
Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
[TBL] [Abstract][Full Text] [Related]
3. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
Yang X; Wong MPM; Ng RK
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
5. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Whitman SP; Hackanson B; Liyanarachchi S; Liu S; Rush LJ; Maharry K; Margeson D; Davuluri R; Wen J; Witte T; Yu L; Liu C; Bloomfield CD; Marcucci G; Plass C; Caligiuri MA
Blood; 2008 Sep; 112(5):2013-6. PubMed ID: 18566324
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
Newcombe AA; Gibson BES; Keeshan K
Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
Wouters BJ; Delwel R
Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
[TBL] [Abstract][Full Text] [Related]
9. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
Lee E; Koh Y; Hong J; Eom HS; Yoon SS
J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicine.
Lamba G; Zaidi SK; Luebbers K; Verschraegen C; Stein GS; Rosmarin A
J Cell Biochem; 2014 Oct; 115(10):1669-72. PubMed ID: 24905899
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic targeting and personalized approaches for AML.
Roboz GJ
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
[TBL] [Abstract][Full Text] [Related]
12. Chromatin, epigenetics and stem cells.
Roloff TC; Nuber UA
Eur J Cell Biol; 2005 Mar; 84(2-3):123-35. PubMed ID: 15819395
[TBL] [Abstract][Full Text] [Related]
13. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics of paediatric acute myeloid leukaemia.
Jones L; McCarthy P; Bond J
Br J Haematol; 2020 Jan; 188(1):63-76. PubMed ID: 31804725
[TBL] [Abstract][Full Text] [Related]
16. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.
Humphries S; Bond DR; Germon ZP; Keely S; Enjeti AK; Dun MD; Lee HJ
Clin Epigenetics; 2023 Sep; 15(1):150. PubMed ID: 37705055
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
